OBJECTIVE: Thirty-day hospital readmission rate is receiving increasing attention as a quality-of-care indicator. The objective of this study was to determine readmission rates and to identify factors associated with readmission among persons living with HIV. DESIGN: Prospective multicenter observational cohort. SETTING: Nine US HIV clinics affiliated through the HIV Research Network. PARTICIPANTS: Patients engaged in HIV care during 2005-2010. MAIN OUTCOME MEASURE(S): Readmission rate was defined as the proportion of hospitalizations followed by a readmission within 30 days. Factors in multivariate analyses included diagnostic categories, patient demographic and clinical characteristics, and having an outpatient follow-up visit. RESULTS: Among 11,651 total index hospitalizations, the 30-day readmission rate was 19.3%. AIDS-defining illnesses (ADIs, 9.6% of index hospitalizations) and non-AIDS-defining infections (26.4% of index hospitalizations) had readmission rates of 26.2 and 16.6%, respectively. Factors independently associated with readmission included lower CD4 cell count [adjusted odds ratio 1.80 (1.53-2.11) for CD4 cell count <50 vs. ≥351 cells/μl], longer length of stay [1.77 (1.53-2.04) for ≥9 days vs. 1-3 days], and several diagnostic categories including ADI. Having an outpatient follow-up clinic visit was not associated with lower readmission risk [adjusted hazard ratio 0.98 (0.88-1.08)]. CONCLUSION: The 19.3% readmission rate exceeds the 13.3% rate reported for the general population of 18-64-year-olds. HIV providers may use the 19.3% rate as a basis of comparison. Policymakers may consider the impact of HIV when estimating expected readmissions for a hospital or region. Preventing or recovering from severe immune dysfunction may be the most important factor to reducing readmissions.
OBJECTIVE: Thirty-day hospital readmission rate is receiving increasing attention as a quality-of-care indicator. The objective of this study was to determine readmission rates and to identify factors associated with readmission among persons living with HIV. DESIGN: Prospective multicenter observational cohort. SETTING: Nine US HIV clinics affiliated through the HIV Research Network. PARTICIPANTS: Patients engaged in HIV care during 2005-2010. MAIN OUTCOME MEASURE(S): Readmission rate was defined as the proportion of hospitalizations followed by a readmission within 30 days. Factors in multivariate analyses included diagnostic categories, patient demographic and clinical characteristics, and having an outpatient follow-up visit. RESULTS: Among 11,651 total index hospitalizations, the 30-day readmission rate was 19.3%. AIDS-defining illnesses (ADIs, 9.6% of index hospitalizations) and non-AIDS-defining infections (26.4% of index hospitalizations) had readmission rates of 26.2 and 16.6%, respectively. Factors independently associated with readmission included lower CD4 cell count [adjusted odds ratio 1.80 (1.53-2.11) for CD4 cell count <50 vs. ≥351 cells/μl], longer length of stay [1.77 (1.53-2.04) for ≥9 days vs. 1-3 days], and several diagnostic categories including ADI. Having an outpatient follow-up clinic visit was not associated with lower readmission risk [adjusted hazard ratio 0.98 (0.88-1.08)]. CONCLUSION: The 19.3% readmission rate exceeds the 13.3% rate reported for the general population of 18-64-year-olds. HIV providers may use the 19.3% rate as a basis of comparison. Policymakers may consider the impact of HIV when estimating expected readmissions for a hospital or region. Preventing or recovering from severe immune dysfunction may be the most important factor to reducing readmissions.
Authors: Robert C Kalayjian; Bryan Lau; Rhoderick N Mechekano; Heidi M Crane; Benigno Rodriguez; Robert A Salata; Zipporah Krishnasami; James H Willig; Jeffrey N Martin; Richard D Moore; Joseph J Eron; Mari M Kitahata Journal: AIDS Date: 2012-09-24 Impact factor: 4.177
Authors: Kathy Petoumenos; Signe W Worm; Eric Fontas; Rainer Weber; Stephane De Wit; Mathias Bruyand; Peter Reiss; Wafaa El-Sadr; Antonella D'Arminio Monforte; Nina Friis-Møller; Jens D Lundgren; Matthew G Law Journal: J Int AIDS Soc Date: 2012-10-10 Impact factor: 5.396
Authors: Ank E Nijhawan; Ellen Kitchell; Sarah Shelby Etherton; Piper Duarte; Ethan A Halm; Mamta K Jain Journal: AIDS Patient Care STDS Date: 2015-07-08 Impact factor: 5.078
Authors: Ank E Nijhawan; Lisa R Metsch; Song Zhang; Daniel J Feaster; Lauren Gooden; Mamta K Jain; Robrina Walker; Shannon Huffaker; Michael J Mugavero; Petra Jacobs; Wendy S Armstrong; Eric S Daar; Meg Sullivan; Carlos Del Rio; Ethan A Halm Journal: J Acquir Immune Defic Syndr Date: 2019-03-01 Impact factor: 3.731
Authors: Thibaut Davy-Mendez; Sonia Napravnik; David A Wohl; Amy L Durr; Oksana Zakharova; Claire E Farel; Joseph J Eron Journal: Clin Infect Dis Date: 2020-10-23 Impact factor: 9.079
Authors: Cecilia L Moore; Andrew E Grulich; Garrett Prestage; Heather F Gidding; Fengyi Jin; Kathy Petoumenos; Iryna B Zablotska; I Mary Poynten; Limin Mao; Matthew G Law; Janaki Amin Journal: J Acquir Immune Defic Syndr Date: 2016-12-15 Impact factor: 3.731
Authors: Lara E Coelho; Sayonara R Ribeiro; Andre M Japiassu; Ronaldo I Moreira; Priscila C Lara; Valdilea G Veloso; Beatriz Grinsztejn; Paula M Luz Journal: J Acquir Immune Defic Syndr Date: 2017-08-01 Impact factor: 3.731
Authors: Kathleen M Akgün; Supriya Krishnan; Adeel A Butt; Cynthia L Gibert; Christopher J Graber; Laurence Huang; Margaret A Pisani; Maria C Rodriguez-Barradas; Guy W Soo Hoo; Amy C Justice; Kristina Crothers; Janet P Tate Journal: AIDS Date: 2021-11-15 Impact factor: 4.177